FrancophonIA/ELRC3.0 huggingface dataset:
English: Verification of the dose to be administered and patient identification are necessary prior to administration of Quadramet.
Danish: Verificering af den korrekte dosis bør kontrolleres, ligesom patientens ID bør kontrolleres en sidste gang umiddelbart inden indgivelse af Quadramet.
English: In clinical studies employing planar imaging techniques, Quadramet accumulates with a lesion-tonormal bone ratio of approximately 5 and a lesion-to-soft tissue ratio of approximately 6.
Danish: I kliniske studier, hvor der anvendes planar billedteknik, akkumuleres Quadramet med en fordeling mellem forandret og normalt knoglevæv på ca. 5 : 1 og mellem forandret og normalt blødt væv på ca. 6 : 1.
English: Allow the product to thaw at room temperature before administration.
Danish: Lad produktet tø op ved stuetemperatur før anvendelse.
English: What Quadramet looks like and contents of the pack Quadramet is a solution for injection.
Danish: Udseende og pakningsstørrelser Quadramet er en opløsning til injektion.
English: PHARMACOLOGIC PROPERTIES
Danish: FARMAKOLOGISKE EGENSKABER
English: Each vial contains 1.5 ml (2 GBq at calibration) to 3.1 ml (4 GBq at calibration) of solution for injection.
Danish: Hvert hætteglas indeholder 1,5 ml (2 GBq ved kalibrering) til 3,1 ml (4 GBq ved kalibrering) opløsning til injektionsvæske.
English: Warnings and precautions Talk to your doctor before taking Quadramet.
Danish: Kontakt lægen, før De bruger Quadramet.
English: Quadramet is to be administered by slow intravenous route through an established intravenous line over a period of one minute.
Danish: Quadramet skal injiceres langsomt (ca. 1 min.) intravenøst gennem et intravenøst kateder.
English: Please refer to the SmPC (SmPC should be included in the box)
Danish: Der henvises til produktresuméet (produktresuméet skal være inkluderet i pakningen)
English: The other ingredients are total EDTMP (as EDTMP.H2O), calcium-EDTMP sodium salt (as Ca), total sodium (as Na), water for injections.
Danish: - Øvrige indholdsstoffer: total EDTMP (som EDTMP·H2O), calcium-EDTMP natriumsalt (som Ca), total natrium (som Na), vand til injektioner.
English: F-91192 GIF-SUR-YVETTE Cedex FRANCE
Danish: F-91192 GIF-SUR-YVETTE Cedex FRANKRIG
English: 91192 GIF-SUR-YVETTE Cedex, FRANCE
Danish: F-91192 GIF-SUR-YVETTE Cedex, FRANKRIG
English: During 6 hours following the injection of Quadramet, your physician will encourage you to drink and void as often as possible.
Danish: Deres læge vil anbefale Dem at indtage drikkevarer og tømme deres blære så ofte som muligt i de første 6 timer efter Quadramet injektionen.
English: EXP: DD/MM/YYYY (12 h CET)
Danish: GBq/hætteglas ________ (12 h CET)
English: Each ml of solution contains 1.3 GBq Samarium (153Sm) lexidronam pentasodium at the reference date
Danish: Hver ml opløsning indeholder 1,3 GBq samarium (153Sm) lexidronam pentanatrium på referencedato.
English: Total EDTMP (as EDTMP.H2O) Calcium-EDTMP sodium salt (as Ca) Total sodium (as Na) Water for Injections
Danish: Total EDTMP (som EDTMP·H2O) Calcium-EDTMP natriumsalt (som Ca) Total natrium (som Na) Vand til injektioner
English: How to take Quadramet
Danish: Sådan skal De bruge Quadramet
English: If you take more Quadramet than you should
Danish: Hvis De har brugt for meget QUADRAMET
English: Samarium (153Sm) lexidronam pentasodium.
Danish: Samarium (153Sm) lexidronam pentanatrium.
English: Each vial contains 1.5 ml (2 GBq at reference) to 3.1 ml (4 GBq at reference) of solution for injection.
Danish: Hvert hætteglas indeholder 1,5 ml (2 GBq på referencedato) til 3,1 ml (4 GBq på referencedato.)
English: Do not take Quadramet: If you are allergic to ethylene diamine tetramethylene phosphonic acid (EDTMP) or similar phosphonate compounds or any of the other ingredients of this medicine (listed in section 6), If you are pregnant, If you have received chemotherapy or hemibody field external radiation therapy in a preceding period of 6 weeks.
Danish: • hvis De er allergisk over for ethylendiamintetramethylenfosfonsyre (EDTMP) eller lignende fosfonatforbindelser eller et af de øvrige indholdsstoffer i Quadramet (angivet i punkt 6),
English: Quadramet 1.3 GBq/mL solution for injection
Danish: Quadramet 1,3 GBq/ml injektionsvæske, opløsning
English: The active substance is samarium (153Sm) lexidronam pentasodium.
Danish: - Aktivt stof: samarium (153Sm) lexidronam pentanatrium.
English: NAME OF THE MEDICINAL PRODUCT Quadramet 1.3 GBq/mL solution for injection.
Danish: LÆGEMIDLETS NAVN Quadramet 1,3 GBq/ml injektionsvæske, opløsning.
English: Quadramet is delivered frozen in dry ice. Store in a freezer at -10°C to -20°C in the original package.
Danish: Opbevares i dybfryser ved -10°C til -20°C i den originale emballage.
English: What Quadramet is and what it is used for What you need to know before you take Quadramet How to take Quadramet
Danish: Det skal De vide, før De begynder at bruge Quadramet Sådan skal De bruge Quadramet Bivirkninger
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT Not applicable
Danish: D. BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE SIKKER OG
English: SPECIAL STORAGE CONDITIONS Store in a freezer at -10°C to -20°C in the original package Use within 6 hours of thawing
Danish: (12 h CET) SÆRLIGE OPBEVARINGSBETINGELSER Opbevares i fryser ved -10 °C til -20 °C i originalemballagen.
English: • Hypersensitivity to the active substance (ethylenediaminetetramethylenephosphonate (EDTMP)
Danish: • overfølsomhed over for det aktive stof (ethylendiamintetramethylenphosphonat (EDTMP) eller lignende phosphonater) eller over for et eller flere af hjælpestofferne anført i pkt.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 1.3 GBq Samarium (153Sm) lexidronam pentasodium at the reference date (corresponding to 20 to 80 µg/ml of samarium per vial) Samarium specific activity is approximately 16 - 65 MBq/µg of samarium.
Danish: (svarende til 20 til 80 µg/ml samarium pr. hætteglas) Samariums specifikke aktivitet er ca. 16 - 65 MBq/µg samarium.
English: Chest
Danish: Milt
English: LIST OF EXCIPIENTS
Danish: LIST OVER HJÆLPESTOFFER
English: GLASS VIAL
Danish: Myokardievæg Nyrer
English: Abundance
Danish: Binyrer
English: Spleen
Danish: Bugspytkirtel
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Quadramet 1.3 GBq/mL solution for injection Samarium (153Sm) lexidronam pentasodium
Danish: LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ Quadramet 1,3 GBq/ml injektionsvæske, opløsning.
English: NAME OF THE MEDICINAL PRODUCT Quadramet 1.3 GBq/mL solution for injection Samarium (153Sm) lexidronam pentasodium
Danish: KVALITATIVOG KVANTITATIV SAMMENSÆTNING Hver ml opløsning indeholder 1,3 GBq samarium (153Sm) lexidronam pentanatrium på referencedato.
English: Repaglinide Accord is taken before meals, normally up to 15 minutes before each main meal.
Danish: Repaglinid Accord indtages før måltiderne, normalt op til 15 minutter før hvert hovedmåltid.
English: It is available as round tablets (0.5 mg, 1 mg and 2 mg).
Danish: Det fås som runde tabletter (0,5 mg, 1 mg og 2 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Accord on 22 December 2011.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Repaglinid Accord den 22. december 2011.
English: The full EPAR for Repaglinide Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Repaglinid Accord findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This means that Repaglinide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Danish: Det betyder, at Repaglinid Accord er identisk med et ‘referencelægemiddel', der allerede er godkendt i Den Europæiske Union (EU), og som hedder NovoNorm.
English: This is a summary of the European public assessment report (EPAR) for Repaglinide Accord.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Repaglinid Accord.
English: For more information about treatment with Repaglinide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Repaglinid Accord, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Repaglinide Accord.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Repaglinid Accord.
English: Other information about Repaglinide Accord
Danish: Andre oplysninger om Repaglinid Accord
English: Repaglinide Accord is a medicine that contains the active substance repaglinide.
Danish: Repaglinid Accord er et lægemiddel, der indeholder det aktive stof repaglinid.
English: Repaglinide Accord is a ‘generic medicine'.
Danish: Repaglinid Accord er et ‘generisk lægemiddel'.
English: EPAR summary for the public repaglinide
Danish: EPAR sammendrag for offentligheden repaglinid
English: The CHMP concluded that, in accordance with EU requirements, Repaglinide Accord has been shown to have comparable quality and to be bioequivalent to the reference medicine.
Danish: CHMP konkluderede, at det i overensstemmelse med EU's krav er blevet påvist, at Repaglinid Accord er af sammenlignelig kvalitet og er bioækvivalent med referencelægemidlet.
English: The Committee recommended that Repaglinide Accord be given marketing authorisation.
Danish: Udvalget anbefalede udstedelse af markedsføringstilladelse for Repaglinid Accord.
English: What are the benefits and risks of Repaglinide Accord?
Danish: Hvilke fordele og risici er der forbundet med Repaglinid Accord?
English: Because Repaglinide Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine.
Danish: Da Repaglinid Accord er et generisk lægemiddel, har patientundersøgelserne været begrænset til tests for at påvise, at det er bioækvivalent med referencelægemidlet.
English: Repaglinide Accord is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Danish: Repaglinid Accord anvendes til patienter, som lider af type 2-diabetes (ikke-insulinkrævende diabetes).
English: Repaglinide Accord helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Danish: Repaglinid Accord får bugspytkirtlen til at producere mere insulin i forbindelse med måltider og anvendes til at holde type 2- diabetes under kontrol.
English: Because Repaglinide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Danish: Da Repaglinid Accord er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
English: Repaglinide Accord may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Danish: Repaglinid Accord kan også anvendes i kombination med metformin (et andet lægemiddel mod diabetes) til patienter med type 2-diabetes, hvis glukoseniveau ikke er tilstrækkeligt kontrolleret med metformin alene.
English: Repaglinide Accord is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Danish: Hvis patienten er skiftet fra et andet lægemiddel mod diabetes, er den anbefalede startdosis 1 mg. Repaglinid Accord anbefales ikke til patienter under 18 år på grund af manglende data om sikkerhed og virkning i denne aldersgruppe.
English: A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Danish: Patientens blodglukose skal regelmæssigt kontrolleres af en
English: What is Repaglinide Accord?
Danish: Hvad er Repaglinid Accord?
English: Why has Repaglinide Accord been approved?
Danish: Hvorfor blev Repaglinid Accord godkendt?
English: How has Repaglinide Accord been studied?
Danish: Hvordan blev Repaglinid Accord undersøgt?
English: What is Repaglinide Accord used for?
Danish: Hvad anvendes Repaglinid Accord til?
English: How is Repaglinide Accord used?
Danish: Hvordan anvendes Repaglinid Accord?
English: blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Danish: Repaglinid Accord kan også anvendes til patienter med type 2-diabetes, hvis blodglukoseniveau normalt kontrolleres tilfredsstillende med diæt, men hvor blodglukosen midlertidigt ikke er under kontrol.
English: <Content (concentration)>
Danish: Indhold (Koncentration)
English: 3 NHBA (Neisserial Heparin Binding Antigen), NadA (Neisseria adhesin A), fHbp (factor H binding protein)
Danish: 3 NHBA (Neisserial heparinbindende antigen), NadA (Neisseria adhesin A), fHbp (faktor H-bindende protein)
English: 1 produced in E. coli cells by recombinant DNA technology 2 adsorbed on aluminium hydroxide (0.5 mg Al3+)
Danish: 1 produceret i E. coli-celler ved rekombinant DNA-teknologi 2 adsorberet på aluminiumhydroxid (0,5 mg Al³+)
English: --1 One dose (0.5 ml) contains: Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3
Danish: --1 Én dosis (0,5 ml) indeholder: Rekombinant Neisseria meningitidis gruppe B NHBA-fusionsprotein 1, 2, 3
English: 10 pre-filled syringes without needles
Danish: 10 fyldte injektionssprøjter uden kanyler
English: 10 pre-filled syringes with needles
Danish: 10 fyldte injektionssprøjter med kanyler
English: 1 pre-filled syringe without needles
Danish: 1 fyldt injektionssprøjte uden kanyler
English: 1 pre-filled syringe with needles
Danish: 1 fyldt injektionssprøjte med kanyler
English: Treatment is usually continued for 2 years.
Danish: Behandlingen fortsættes sædvanligvis i to år.
English: The name of the medicine was changed to Granupas on 15 May 2014.
Danish: Lægemidlets navn blev ændret til Granupas den 15. maj 2014.
English: The first of these involved 166 patients with tuberculosis aged between 15 to 30 years.
Danish: Den første omfattede 166 tuberkulosepatienter i alderen 15-30 år.
English: They should be given a total of 150 mg per kilogram body weight every day, split into two doses.
Danish: Der gives i alt 150 mg/kg legemsvægt pr. dag, fordelt på to doser.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Para-aminosalicylic acid Lucane on 7 April 2014.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Para-aminosalicylsyre Lucane den 7. april 2014.
English: This is a summary of the European public assessment report (EPAR) for Granupas.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Granupas.
English: The recommended dose for adults is one sachet three times a day.
Danish: Den anbefalede dosis til voksne er ét brev tre gange dagligt.
English: PAS has been used for many years in the EU for the combination treatment of tuberculosis.
Danish: PAS har været anvendt i mange år i EU til kombinationsbehandling af tuberkulose.
English: Other information about Granupas
Danish: Andre oplysninger om Granupas
English: A risk management plan has been developed to ensure that Granupas is used as safely as possible.
Danish: Der er udarbejdet en risikostyringsplan for at sikre, at Granupas anvendes så sikkert som muligt.
English: Granupas must not be taken by patients with severely reduced kidney function.
Danish: Granupas må ikke anvendes af patienter med svært nedsat nyrefunktion.
English: It is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects.
Danish: Det anvendes i kombination med andre lægemidler til behandling af voksne og børn i alderen 28 dage og derover med multiresistent tuberkulose, når kombinationsbehandlinger uden dette lægemiddel ikke kan anvendes, enten fordi sygdommen er resistent over for dem eller på grund af deres bivirkninger.
English: The most common side effects with Granupas (which may affect up to 1 in 10 people) are abdominal pain (stomach ache), vomiting, nausea, bloating, diarrhoea and soft stools, giddiness, disturbance in gait and balance, and allergic skin reactions and rash.
Danish: De hyppigste bivirkninger ved Granupas (som kan forekomme hos op til 1 ud af 10 personer) er mavesmerter, opkastning, kvalme, oppustethed, diarré og blød afføring, svimmelhed, gang- og balanceforstyrrelser, allergiske hudreaktioner og udslæt.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Granupas's benefits are greater than its risks and recommended that it be approved for use in the EU.
Danish: Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Granupas opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare', and Granupas was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 December
Danish: Da antallet af patienter med tuberkulose er lavt i EU, betragtes sygdommen som »sjælden«, og Granupas blev udpeget som »lægemiddel til sjældne sygdomme« den 17. december 2010.
English: In children and adolescents, the daily dose depends on their weight.
Danish: Hos børn og voksne fastsættes den daglige dosis efter legemsvægten.
English: Granupas is a tuberculosis medicine that contains the active substance para-aminosalicylic acid (PAS).
Danish: Granupas er et lægemiddel mod tuberkulose og indeholder det aktive stof para-aminosalicylsyre (PAS).
English: The patients were treated for 3 months with either PAS or another medicine called streptomycin, or with a combination of PAS and streptomycin, and then followed up for 3 extra months.
Danish: Patienterne blev behandlet i 3 måneder enten med PAS eller et andet lægemiddel, streptomycin, eller med en kombination af PAS og streptomycin og blev derefter fulgt op i yderligere 3 måneder.
English: A dosing spoon is used to measure small doses for young children.
Danish: Der medfølger doseringsske til måling af små doser til små børn.
English: The applicant also provided published data on the doses of PAS to be used in children.
Danish: Ansøgeren forelagde publicerede data om de doser af PAS, der skal anvendes hos børn.
English: What measures are being taken to ensure the safe and effective use of Granupas?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Granupas?
English: What is Granupas and what is it used for?
Danish: Hvad er Granupas, og hvad anvendes det til?
English: PAS had been widely used in the past for combination treatment but was largely discontinued due to adverse effects on the stomach.
Danish: PAS har tidligere været udbredt til kombinationsbehandling, men er stort set gået ud af brug på grund af bivirkninger fra maven.
English: Multi-drug resistance is when the bacteria causing tuberculosis (Mycobacterium tuberculosis) are resistant to treatment with at least isoniazid and rifampicin, two standard tuberculosis medicines.
Danish: Multiresistens vil sige, at tuberkulosebakterien (Mycobacterium tuberculosis) er resistent over for behandling med mindst isoniazid og rifampicin, som er to standardlægemidler mod tuberkulose.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Granupas, including the appropriate precautions to be followed by healthcare professionals and patients.
Danish: På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Granupas, herunder passende forholdsregler, som patienter og sundhedspersonale skal følge.
English: Why is Granupas approved?
Danish: Hvorfor blev Granupas godkendt?
English: Granupas can only be obtained with a prescription.
Danish: Granupas udleveres kun efter recept.
English: The full EPAR and risk management plan summary for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR og resuméet af risikostyringsplanen for Granupas findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In the second main study involving 341 patients aged over 12 years, PAS in combination with isoniazid was compared with isoniazid alone.
Danish: I den anden hovedundersøgelse med 341 patienter over 12 år blev en kombination af PAS og isoniazid sammenlignet med isoniazid alene.
English: para-aminosalicylic acid
Danish: Granupas para-aminosalicylsyre
English: The Committee noted that the active substance, PAS, has been shown to be beneficial when used in combination with other medicines to treat tuberculosis and that it helps reduce the emergence of resistance to other medicines.
Danish: Udvalget bemærkede, at det aktive stof, PAS, er påvist at være gavnligt, når det anvendes i kombination med andre lægemidler til behandling af tuberkulose, og at det mindsker opståen af resistens over for andre lægemidler.
English: The Committee also noted that the World Health Organization continues to recommend PAS as an option to be used in combination with other medicines for treating multi-drug resistant tuberculosis.
Danish: Udvalget bemærkede desuden, at Verdenssundhedsorganisationen fortsat anbefaler mulig anvendelse af PAS i kombination med andre lægemidler til behandling af multiresistent tuberkulose.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Danish: Sammendraget af udtalelsen fra Udvalget for Lægemidler til Sjældne Sygdomme om Granupas findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: For more information about treatment with Granupas, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Granupas, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: It is not intended to provide practical advice on how to use Granupas.
Danish: Det er ikke en praktisk vejledning i, hvordan Granupas bør anvendes.
English: PAS is similar to a chemical (para-aminobenzoic acid) that is used by the bacteria to make folic acid needed for new bacteria to grow.
Danish: PAS ligner et kemisk stof (paraaminobenzoesyre), som bakterierne anvender til at producere folsyre, der er nødvendigt for vækst af nye bakterier.
English: What are the risks associated with Granupas?
Danish: Hvilke risici er der forbundet med Granupas?
English: The active substance, PAS, is a ‘bacteriostatic agent', which means that it works by stopping the growth of M. tuberculosis bacteria.
Danish: Det aktive stof, PAS, er »bakteriostatisk«, dvs. det virker ved at standse væksten af bakterien M. tuberculosis.
English: It is available as 4 g sachets containing ‘gastroresistant' granules that allow the active substance to reach the intestine without being released in the stomach, thus reducing side effects in the stomach.
Danish: Det leveres som breve på 4 g, der indeholder et enterogranulat, som tillader det aktive stof at nå frem til tarmen, uden at det frigives i mavesækken, hvorved bivirkningerne fra maven mindskes.